Details for Patent: 8,491,932
✉ Email this page to a colleague
Which drugs does patent 8,491,932 protect, and when does it expire?
Patent 8,491,932 protects TARPEYO and is included in one NDA.
This patent has ten patent family members in nine countries.
Summary for Patent: 8,491,932
| Title: | Compositions for the oral delivery of corticosteroids |
| Abstract: | An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis. |
| Inventor(s): | Watts; Peter (Nottingham, GB), Dyer; Ann Margaret (Nottingham, GB) |
| Assignee: | Archimedes Development Limited (Nottingham, GB) |
| Application Number: | 12/992,182 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 8,491,932
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas | TARPEYO | budesonide | CAPSULE, DELAYED RELEASE;ORAL | 215935-001 | Dec 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION | ⤷ Sign Up | |||
| Calliditas | TARPEYO | budesonide | CAPSULE, DELAYED RELEASE;ORAL | 215935-001 | Dec 15, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,491,932
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0808537.5 | May 12, 2008 |
| PCT Information | |||
| PCT Filed | May 07, 2009 | PCT Application Number: | PCT/GB2009/001150 |
| PCT Publication Date: | November 19, 2009 | PCT Publication Number: | WO2009/138716 |
International Family Members for US Patent 8,491,932
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| China | 102088962 | ⤷ Sign Up | |||
| Denmark | 2278958 | ⤷ Sign Up | |||
| European Patent Office | 2278958 | ⤷ Sign Up | |||
| Spain | 2452265 | ⤷ Sign Up | |||
| United Kingdom | 0808537 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
